Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 6/20 | 0.45 |
| ▸ | OPRL1 | P41146 | 5/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 7/20 | 0.38 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.35 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.35 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.35 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.35 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.35 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | TNKS | O95271 | 1/20 | 0.34 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5578842 | 0.90 | OPRM1 (0.45) | OPRM1OPRL1OPRK1SIGMAR1GRIN2D | |
| SCHEMBL12084297 | 0.89 | OPRM1 (0.53) | OPRM1OPRL1OPRK1SIGMAR1GRIN2D | |
| SCHEMBL13640817 | 0.82 | OPRM1 (0.44) | OPRM1OPRL1OPRK1TNKSTNKS2 | |
| SCHEMBL12899439 | 0.81 | OPRM1 (0.37) | OPRM1OPRL1OPRK1SIGMAR1GRIN2D | |
| SCHEMBL12899323 | 0.81 | OPRM1 (0.37) | OPRM1OPRL1OPRK1SIGMAR1GRIN2D | |
| SCHEMBL13640748 | 0.78 | OPRM1 (0.36) | OPRM1OPRL1OPRK1TNKSTNKS2 | |
| SCHEMBL13640808 | 0.78 | OPRM1 (0.54) | OPRM1OPRL1OPRK1SIGMAR1DRD2 | |
| SCHEMBL12293656 | 0.78 | OPRM1 (0.54) | OPRM1OPRL1OPRK1SIGMAR1DRD2 | |
| SCHEMBL12198647 | 0.77 | KCNH2 (0.54) | OPRM1OPRL1OPRK1 | |
| SCHEMBL13640833 | 0.76 | OPRL1 (0.46) | OPRM1OPRL1OPRK1SIGMAR1DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8497295-B2 | Spiroindoline modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-07-30 | — | — | US | disclosed |
| US-20120283243-A1 | Spiroindoline Modulators of Muscarinic Receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283243-A1 | Spiroindoline Modulators of Muscarinic Receptors | CHRM3, CHRM2, CHRM5 | OPRM1 177/4885OPRL1 108/4885OPRK1 159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.